Detection of circulating tumor cells in breast cancer patients using the GILUPI CellCollector®
GILUPI GmbH announces that a scientific article about a multicenter, clinical trial in China has been published in the c…
GILUPI GmbH announces that a scientific article about a multicenter, clinical trial in China has been published in the c…
The GILUPI CellCollector® - the first medical device for in vivo CTC isolation, manufactured by GILUPI - has been approv…
Der GILUPI CellCollector® - das erste zugelassene Medizinprodukt zur in vivo – Isolation von zirkulierenden Tumorzellen…
GILUPI GmbH announced today that the company was granted a further Chinese patent protecting the unique and innovative G…
GILUPI GmbH announces the release of clinical data from a prostate cancer clinical study in December 2016. The scientifi…
The investors AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, the - venture capital fund of the Sparkassen of Brandenb…
Die Investoren AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, der Risikokapitalfonds der Sparkassen des Landes Brande…
GILUPI will participate at the 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria. The WCLC is the world’s l…
At the 6th Herbsttreffen AG Molekularpathologie in Karlsruhe, Germany, from 21th to 22th November 2016, GILUPI will be o…
GILUPI GmbH announces the release of clinical data from a prostate cancer setting in August 2016. The scientific paper d…